MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

A team at Johns Hopkins Medicine has focused their work on myelin development using oligodendrocytes to help study conditions like MS.

Chai Discovery, Noetik, and Boltz have entered multi-year pharma partnerships focused on models, not molecules, hinting at AI’s “infrastructure moment.” ...

The new investment in the Holly Springs facility is on top of the initial commitment in May 2025, and groundbreaking in August 2025.

The so-called magneto-sensitive fluorescent proteins or MFPs, overcome key limitations of previous biological candidates for quantum sensors.

The discovery fundamentally changes the understanding of a structure in the avian eye that has been misinterpreted for centuries.

Danish researchers have created new cell lines that need a less tailored feeding schedule and produce fewer waste products.

D printing is a good option for bioreactor production. The flexibility of the approach outweighs concerns about higher costs.

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.

Lab-scale production of medicarpin in yeast heralds another manufacturing option for this natural anti-tumor agent.

According to the data, when microglia activity in the brain was suppressed, baby mice were better able to recall fearful experiences.